Date Filed | Type | Description |
05/02/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
05/02/2019 |
8-K
| Bankruptcy or Receivership, Material Modifications to Rights of Security Holders, Changes in Control of Registrant, Departure... |
04/29/2019 |
8-K
| Bankruptcy or Receivership, Material Modifications to Rights of Security Holders, Regulation FD Disclosure, Other Events, Fin... |
04/02/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
03/14/2019 |
8-K
| Bankruptcy or Receivership, Financial Statements and Exhibits |
03/08/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
03/06/2019 |
8-K
| Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits |
03/01/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
02/26/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
02/12/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/11/2019 |
SC 13G/A
| VANGUARD GROUP INC reports a 1.3% stake in Synergy Pharmaceuticals Inc |
02/04/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
01/10/2019 |
SC 13G/A
| BlackRock Inc. reports a 4.9% stake in SYNERGY PHARMACEUTICALS INC |
01/10/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
01/02/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
12/18/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
12/13/2018 |
8-K
| Acquisition/merger/asset purchase announced |
12/06/2018 |
8-K
| Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an... |
11/26/2018 |
8-K
| Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an... |
11/19/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
11/15/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
11/14/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
11/09/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
11/06/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
11/01/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
10/31/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
10/25/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
10/09/2018 |
8-K
| Quarterly results |
10/01/2018 |
8-K
| Quarterly results |
09/24/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
09/21/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/31/2018 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
08/16/2018 |
4
| Spigelman Melvin K (Director) has filed a Form 4 on SYNERGY PHARMACEUTICALS, INC.
Txns:
| Paid exercise price by delivering 101,695 shares
@ $0 Exercised 150,000 options
@ $1.2, valued at
$180k
|
|
08/08/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
|